ALX Oncology reports an incentive offer as permitted by Nasdaq listing rules By Investing.com
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings, Inc. (ALX Oncology or the Company), (Nasdaq: ALXO), is a clinical-stage biotechnology company that advances therapies that enhance the immune system. The compensation committee announced today that the system, which will treat cancer and prolong the lives of patients, will begin on January 21, 2025. ALX Oncology’s board of directors granted an incentive stock option to purchase an aggregate of 600,000 shares of ALX Oncology common stock to Harish Shantaram, the Company’s Chief Financial Officer, in connection with the commencement of operations. Mr. Shantaram’s incentive stock option is vested in ALX Oncology Holdings Inc. 2025 is subject to the Incentive Equity Incentive Plan and related types of agreements, and Mr. Shantaram has been granted as incentive material for his employment with ALX Oncology according to the Nasdaq. 5635(c)(4) of the Listing Rules.
The incentive stock option has an exercise price of $1.65 per share, which is equal to the closing price of ALX Oncology common stock on the date of grant, and 25% of the shares will be subject to such incentive stock option. In the year January 21, 2025 will be the one-year anniversary and an additional one forty-eighth share for such incentive stock option will be monthly. Continued service to the employee.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO ) is a clinical-stage biotechnology company that stimulates the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, Ivorpacept, has demonstrated the potential to serve as a cornerstone therapy upon which future immunological oncology can be built. Ivorpacept is currently being evaluated in several clinical trials in various cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Company Contact:
Alison Dillon, Chief Business Officer, ALX Oncology
ir@alxoncology.com
Media Contact:
Audra Fries, Sam Brown, Inc.
audrafris@sambrown.com
(917) 519-9577
Source: ALX Oncology